The FDA today accelerated the approval of Merck MET inhibitors in Germany for the treatment of specific patients with non-small cell lung cancer

Lung cancer is one of the most common types of cancer in the world and the leading cause of cancer-related deaths, with 1.9 million deaths worldwide each year.
changes in the MET signaling path, including the METex14 jump, are estimated to occur in 3% to 4% of NSCLC cases.
Tepmetko is an oral MET inhibitor designed to suppress cancer-causing MET subject signals caused by a mutation in the MET gene.
it has been awarded a breakthrough therapy by the FDA.
March, it was approved by Japan's Ministry of Health, Labour and Human Services (MHLW) to treat patients with METex14 jumping non-removable, late-stage or relapsed NSCLC.
is also the first MET inhibitor to receive regulatory approval worldwide.
approval was supported by a critical Phase 2 clinical trial called VISION.
152 patients with meTex14 jump variants received Tepmetko's single-drug treatment.
they do not carry EGFR or ALK gene mutations.
test results showed that Tepmetko achieved a total remission rate of 43% in both primary and treated patients.
duration (DOR) was 10.8 months (95% CI, 6.9-NE) and 11.1 months (95% CI, 9.5-18.5), respectively.
67% of first-time patients and 75% of treated patients had a duration of more than 6 months, and 30% of first-treated patients and 50% of treated patients had a duration of more than 9 months.
"METex14 Jump NSCLC patients tend to be older and face poor clinical prognostics.
K. Paik, clinical director of chest oncology at memorial Sloan Kettering Cancer Center, who heads the VISION clinical trial, said, "Patients urgently need targeted therapies that produce long-lasting anti-cancer activity.
Tepmetko provides an important new treatment option for patients with metastasis NSCLC who carry these gene variants.
Met has become one of the hottest research targets in the field of cancer.
last May, the FDA accelerated approval of Novarma's listing of capmatinib, a MET inhibitor.
In China, although no drugs have been approved for MET-related indications, more than a dozen companies, including He Huang Pharmaceuticals and Howson Pharmaceuticals, are developing innovative drugs targeting MET, and many research and development projects have entered the clinical stage.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
: s1. FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Ores for Patients with Metastatic NSCLC with METex14 Skipping Alterations. Retrieved February 3, 2021, from